actin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-07. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Rates of MI for a given age have decreased globally between 1990 and 2010. In 2011, an MI was one of the top five most expensive conditions during inpatient hospitalizations in the US, with a cost of about $11.5 billion for 612,000 hospital stays.
Additionally, in January 1978, the band appeared as themselves in two episodes of the ABC sitcom What's Happening!!, performing "Echoes of Love," "Little Darlin' (I Need You)", "Black Water", "Takin' It to the Streets", and "Take Me in Your Arms". Performances were done live (versus lip synching to a pre-recorded track), with some overdubs added in post production, notably during Baxter's solo on "Take Me in Your Arms (Rock Me a Little While)," which was lifted from the album version. After almost a decade on the road, and with seven albums to their credit, the Doobies' profile was substantially elevated by the success of their next album, 1978's Minute by Minute. It spent five weeks atop the charts and dominated several radio formats for the better part of two years. McDonald's song "What a Fool Believes", written with Kenny Loggins, was the band's second No. 1 single and earned the songwriting duo (along with producer Ted Templeman) a Grammy Award for Record of the Year. The album won a Grammy for Pop Vocal Performance by a Group and was nominated for Album of the Year. Both "What a Fool Believes" and the title track were nominated for Song of the Year, with "What a Fool Believes" winning the award. Among the other memorable songs on the album are "Here to Love You", "Dependin' On You" (co-written by McDonald and Simmons), "Steamer Lane Breakdown" (a Simmons bluegrass instrumental) and McDonald's "How Do the Fools Survive?" (co-written by Carole Bayer Sager). Nicolette Larson and departed former bandleader Johnston contributed guest vocals on the album.
As these coils are rapidly switched during the excitation and response to perform a moving line scan, they create the characteristic repetitive noise of an MRI scan as the windings move slightly due to magnetostriction. The contrast between different tissues is determined by the rate at which excited atoms return to the equilibrium state. Exogenous contrast agents may be given to the person to make the image clearer.
In matrix-assisted laser desorption ionization (MALDI), a fragmented peptide sample is loaded onto a matrix and ionized through the use of a high energy laser. The fragmented ions are then separated by mass-to-charge ratio based on the time of flight (TOF) through the spectrometer. They can then be further fragmented and re-analyzed in tandem mass spectrometry, often with a quadrupole ion trap, but also possible with tandem time of flight. The output received from a mass spectrometer comes in the form of a peak list. This spectrum shows the masses and relative abundances of the peptide fragments present in the sample. In reading a spectrum like the one shown, all possible major fragmentations of a protein would need to be considered. Then the masses of those fragments would correlate to the numbers in the peaks of the spectrum. While it can be analyzed to some degree on its own, in forming a peptide-mass fingerprint, the peak list is run through a database search to find homologous peptide sequences.
Portugal has been a semi-presidential representative democratic republic since the ratification of the Constitution of 1976. The Constitution divides the core structures of the Portuguese political system among four sovereignty organs: the president, the government, the Assembly of the Republic, and the courts. There is universal suffrage for adults over 18 years of age, with a secret ballot for all elected offices. Portugal operates a competitive multi-party system at the national, regional, and local levels. There have been trends towards autocratisation. The head of state of Portugal is the president who is elected to a five-year term by direct, universal adult suffrage. The president is usually regarded as politically independent and carries moderating powers aimed at ensuring the regular functioning of institutions and constitutional guarantees; in addition, it includes supreme command of the armed forces, and shapes political opinions and agendas. The current president of Portugal is António José Seguro; he took office after winning the runoff vote of the 2026 Portuguese presidential election.
Sources: en.wikipedia.org
=== Combination hemoglobinopathies === A combination hemoglobinopathy occurs when someone inherits two different abnormal hemoglobin genes. Alpha thalassemia can coexist with other hemoglobinopathies such as sickle cell disease and beta thalassemia. When alpha thalassemia carrier or trait combines with another hemoglobinopathy, the symptoms are generally those of the other condition.
=== Myopathies with cores === 'Core myopathies' such as multicore myopathy and central core disease are characterized by sharply-demarcated areas devoid of oxidative enzymes NADH, SDH, and COX, in muscle fibres.
==== 2400–2499 ==== County Council of Clwyd (River Dee Estuary Bridge) Scheme 1992 Confirmation Instrument 1993 (S.I. 1993/2400) Environmental Protection (Prescribed Processes and Substances) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/2405) Offshore Safety Act 1992 (Commencement No. 1) Order 1993 (S.I. 1993/2406) Leasehold Reform (Collective Enfranchisement and Lease Renewal) Regulations 1993 (S.I. 1993/2407) Rent Assessment Committee (England and Wales) (Leasehold Valuation Tribunal) Regulations 1993 (S.I. 1993/2408) Leasehold Reform (Notices) (Amendment) Regulations 1993 (S.I. 1993/2409) Local Government and Housing Act 1989 (Commencement No. 16) Order 1993 (S.I. 1993/2410) National Health Service (General Medical Services) Amendment (No. 2) Regulations 1993 (S.I. 1993/2421) Environmentally Sensitive Areas (Ynys Mo*n) Designation (Amendment) Order 1993 (S.I. 1993/2422) Patents (Amendment) Rules 1993 (S.I. 1993/2423) Pembrokeshire National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2436) Strathclyde Region (Electoral Arrangements) Order 1993 (S.I. 1993/2439) Finance Act 1993, Section 18, (Appointed Day) Order 1993 (S.I. 1993/2446) National Health Service (General Medical and Pharmaceutical Services) (Scotland) Amendment (No. 2) Regulations 1993 (S.I. 1993/2449) Social Fund Cold Weather Payments (General) Amendment Regulations 1993 (S.I. 1993/2450) National Health Service (Pharmaceutical Services) Amendment Regulations 1993 (S.I. 1993/2451) Vehicles Excise Duty (Simplification of Goods Vehicles Rates) Order 1993 (S.I.
InterRidge Vents Database – global database of the locations of known active submarine hydrothermal vent fields, hosted by InterRidge Ocean Explorer – public outreach site for explorations sponsored by the US Office of Ocean Exploration Video by EV Nautilus Video by Schmidt Ocean
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.